Print Page   |   Contact Us   |   Report Abuse   |   Sign In   |   Register
Community Search
Biophysics Working Group
Share |

CASSS announces the creation of a Biophysics Working Group. This group brings together scientists from across public and private sectors to foster collaboration and address unmet challenges in the application of biophysical methods to biologics research and development.

Who we are: Scientists from across public and private sectors
What we do: Foster collaboration and address unmet challenges in the application of biophysical methods to biologics research and development
How we do it: Coordinated, collaborative, research projects and other initiatives leveraging capabilities across member organizations shared in publications and CASSS conferences around the world

The goals of the group are to provide guidance and best practices, support innovation and advance transformative ideas, and generally enhance the overall scientific dialogue through contributions in various publications and CASSS conferences around the world. This group also aligns with CASSS’ purpose to enable a global community of industry, academic and regulatory professionals to work together to resolve scientific challenges in the field of biopharmaceutical development and regulation.

Members of the former “HOS Consortium” have included: Amgen Inc., AbbVie, Biogen, Bristol-Meyers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Elion Labs, Genentech, a Member of the Roche Group, GlaxoSmithKline, Janssen, MedImmune, A member of the AstraZeneca Group, Pfizer, Inc., NIST, Sandoz, University of Delaware, University of Kansas, University of New Hampshire, and Yeshiva University. 

 

The group is currently soliciting proposals for collaborative research projects or other initiatives that will effectively leveraging capabilities across member organizations.

 

To get involved click here! 

 



Examples of related work include:

 

Gabrielson JP, Weiss WF 4th 2015. Technical decision-making with higher order structure data: starting a new dialogue. Journal of pharmaceutical sciences  104(4):1240-1245.

Arthur KK, Dinh N, Gabrielson JP 2015. Technical decision making with higher order structure data: utilization of differential scanning calorimetry to elucidate critical protein structural changes resulting from oxidation. Journal of pharmaceutical sciences  104(4):1548-1554.

Budyak IL, Doyle BL, Weiss WF 4th 2015. Technical decision-making with higher order structure data: specific binding of a nonionic detergent perturbs higher order structure of a therapeutic monoclonal antibody. Journal of pharmaceutical sciences  104(4):1543-1547.

Gruia F, Du J, Santacroce PV, Remmele RL, Jr., Bee JS 2015. Technical decision making with higher order structure data: impact of a formulation change on the higher order structure and stability of a mAb. Journal of pharmaceutical sciences  104(4):1539-1542.

Jiang Y, Li C, Li J, Gabrielson JP, Wen J 2015. Technical decision making with higher order structure data: higher order structure characterization during protein therapeutic candidate screening. Journal of pharmaceutical sciences  104(4):1533-1538.

Wei JY, Bou-Assaf GM, Houde D, Weiskopf A 2015. Technical Decision-Making with Higher Order Structure Data: Detecting Reversible Concentration-Dependent Self-Association in a Monoclonal Antibody and a Preliminary Investigation to Eliminate It. Journal of pharmaceutical sciences  104(11):3984-3989.

  


 

 

 

Membership Software Powered by YourMembership.com®  ::  Legal